Sirna Shareholders OK Merck Acquisition; Firm Alters Closing Expectation Date | GenomeWeb
NEW YORK (GenomeWeb News) — Sirna Therapeutics yesterday said its shareholders have approved Merck’s bid to acquire the company.
 
Sirna said the deal, subject to customary closing conditions, is “expected to close as soon as reasonably practicable.” Earlier in December the company said the acquisition “may close as early as this month.” The deal was originally slated to close by the first quarter of 2007.
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.